CommercialCoverageMedium impact
08.01.36g, Therapies for Spinal Muscular Atrophy Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®)
Independence Blue Cross·Neurology, Pediatrics, Internal Medicine·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
This is an updated policy for therapies treating Spinal Muscular Atrophy, specifically covering Nusinersen (Spinraza®) and Onasemnogene abeparvovec-xioi (Zolgensma®). The policy affects commercial insurance plans and becomes effective April 1, 2026.
Action Required
By April 1, 2026: Billing team must review updated coverage criteria for Spinraza® and Zolgensma® therapies for spinal muscular atrophy patients. Access the full policy at the provided URL to understand specific coverage requirements, prior authorization needs, and documentation requirements for these high-cost specialty medications.